Praxis Teams with Remagine Labs on Transdermal Essential Tremor Drug
Event summary
- Praxis Precision Medicines and Remagine Labs have partnered to develop a transdermal patch for ulixacaltamide, Praxis's lead essential tremor (ET) treatment.
- Ulixacaltamide's NDA was accepted by the FDA in April 2026 with a PDUFA target action date of January 29, 2027.
- Praxis has made an equity investment in Remagine Labs to accelerate collaboration on the transdermal delivery system.
- The transdermal option aims to expand ulixacaltamide's addressable market beyond its initial patient population.
The big picture
This collaboration reflects a growing trend in biopharma to leverage advanced drug delivery technologies for CNS disorders. The partnership could enhance ulixacaltamide's competitive positioning in the essential tremor market, which remains underserved with limited therapeutic options. The equity investment underscores Praxis's strategic commitment to extending the long-term value of its lead asset.
What we're watching
- Regulatory Timing
- Whether the FDA will meet its January 29, 2027 PDUFA target action date for ulixacaltamide.
- Market Expansion
- How successful the transdermal delivery system will be in broadening ulixacaltamide's patient reach.
- Execution Risk
- The pace at which Praxis and Remagine can advance the transdermal patch program given their shared commitment.